A single intravenous injection of cyclosporin A-loaded lipid nanocapsules prevents retinopathy of prematurity.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
23 09 2022
23 09 2022
Historique:
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
Retinopathy of prematurity (ROP) is a retinal disease that threatens the vision of prematurely born infants. Severe visual impairment up to complete blindness is caused by neovascularization and inflammation, progressively destroying the immature retina. ROP primarily affects newborns in middle- and low-income countries with limited access to current standard treatments such as intraocular drug injections and laser- or cryotherapy. To overcome these limitations, we developed a nanotherapeutic that effectively prevents ROP development with one simple intravenous injection. Its lipid nanocapsules transport the antiangiogenic and anti-inflammatory cyclosporin A efficiently into disease-driving retinal pigment epithelium cells. In a mouse model of ROP, a single intravenous injection of the nanotherapeutic prevented ROP and led to normal retinal development by counteracting neovascularization and inflammation. This nanotherapeutic approach has the potential to bring about a change of paradigm in ROP therapy and prevent millions of preterm born infants from developing ROP.
Identifiants
pubmed: 36149956
doi: 10.1126/sciadv.abo6638
pmc: PMC9506721
doi:
Substances chimiques
Lipids
0
Nanocapsules
0
Vascular Endothelial Growth Factor A
0
Cyclosporine
83HN0GTJ6D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabo6638Références
Clin Biochem. 1991 Feb;24(1):9-14
pubmed: 2060139
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6115-20
pubmed: 23530216
Clin Transplant. 1999 Aug;13(4):356-62
pubmed: 10485379
Int J Mol Sci. 2021 Sep 22;22(19):
pubmed: 34638537
Eur J Pharmacol. 2016 Sep 15;787:94-104
pubmed: 26948311
Drug Discov Today. 2011 Mar;16(5-6):270-7
pubmed: 21167306
Biomaterials. 2014 Mar;35(9):2568-79
pubmed: 24411677
Front Immunol. 2017 Dec 22;8:1868
pubmed: 29312345
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
J Neuroinflammation. 2017 Aug 22;14(1):165
pubmed: 28830469
Drug Discov Today. 2022 Sep;27(9):2497-2509
pubmed: 35654389
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):3075-80
pubmed: 12202532
Exp Eye Res. 2007 May;84(5):812-22
pubmed: 17331500
Am J Pathol. 2015 Jun;185(6):1749-68
pubmed: 25857227
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9764-9
pubmed: 8790405
Eye Brain. 2016 May 19;8:31-36
pubmed: 28539799
J Ocul Pharmacol Ther. 2021 Mar;37(2):112-130
pubmed: 33535016
Adv Drug Deliv Rev. 2006 Nov 15;58(11):1131-5
pubmed: 17097758
Agents Actions. 1994 Dec;43(3-4):179-86
pubmed: 7725970
Pediatr Res. 2010 Apr;67(4):394-400
pubmed: 20032809
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Pharm Res. 2002 Jun;19(6):875-80
pubmed: 12134960
Curr Opin Cell Biol. 2020 Feb;62:37-45
pubmed: 31518914
Int J Pharm. 2020 Jul 30;585:119433
pubmed: 32447023
N Engl J Med. 2011 Feb 17;364(7):603-15
pubmed: 21323540
Mol Pharm. 2021 Feb 1;18(2):506-521
pubmed: 32501716
Glia. 2013 May;61(5):651-78
pubmed: 23440929
Nat Protoc. 2009;4(11):1565-73
pubmed: 19816419
Ophthalmology. 2015 Jan;122(1):200-10
pubmed: 25444347
Nature. 2008 Dec 11;456(7223):809-13
pubmed: 18997771
Eur J Pharm Biopharm. 2019 Jun;139:23-32
pubmed: 30851353
J Pediatr. 2019 Mar;206:56-65.e8
pubmed: 30471715
Invest Ophthalmol Vis Sci. 1989 Feb;30(2):225-32
pubmed: 2536645
Lancet. 2017 Jul 15;390(10091):231-266
pubmed: 28528753
Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):56-62
pubmed: 29376233
Reprod Health. 2013;10 Suppl 1:S2
pubmed: 24625129
Clin Drug Investig. 2013 Jan;33(1):25-34
pubmed: 23179472
Lancet. 2014 Jul 12;384(9938):174-88
pubmed: 24853603
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5177-82
pubmed: 18708611
Eye (Lond). 2010 Mar;24(3):416-21
pubmed: 20010791
J Lipid Res. 1998 Apr;39(4):777-88
pubmed: 9555943
Int J Pharm. 2010 Aug 30;396(1-2):204-9
pubmed: 20600733
Invest Ophthalmol Vis Sci. 1997 Feb;38(2):436-45
pubmed: 9040477
Lancet. 2013 Oct 26;382(9902):1445-57
pubmed: 23782686
Best Pract Res Clin Obstet Gynaecol. 2018 Oct;52:3-12
pubmed: 29779863
Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2822-9
pubmed: 15277509
Biochemistry. 2004 Mar 16;43(10):2699-707
pubmed: 15005605
Sci Rep. 2016 Oct 11;6:34631
pubmed: 27725716
Eye Brain. 2016;8:67-79
pubmed: 27499653
Proc Natl Acad Sci U S A. 2016 May 3;113(18):E2516-25
pubmed: 27091985
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19898-903
pubmed: 19057008
Asia Pac J Ophthalmol (Phila). 2018 May-Jun;7(3):145-151
pubmed: 29633587
Cell Commun Signal. 2004 Jun 2;2(1):3
pubmed: 15175101
Gene Ther. 2009 May;16(5):645-59
pubmed: 19194480
JCI Insight. 2019 Jul 25;4(14):
pubmed: 31341109
J Control Release. 2012 Jul 20;161(2):152-63
pubmed: 22001607
PLoS One. 2011;6(9):e24793
pubmed: 21969860
Adv Ther. 2012 Apr;29(4):359-69
pubmed: 22402896
Surv Ophthalmol. 2018 Sep - Oct;63(5):618-637
pubmed: 29679617
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Prog Retin Eye Res. 2014 Jul;41:64-89
pubmed: 24704580
Physiol Rev. 2005 Jul;85(3):845-81
pubmed: 15987797